Attentive Science Australia
Provides preclinical (nonclinical) Pharmacokinetics, Safety Pharmacology and Toxicology services to the Biopharma industry.
Our veteran team has over 20 combined decades of scientific experience and expertise with regulatory submissions.
The team has expertise with various types of test substances, test systems, routes of administration, and overall conduct of nonclinical studies
The Australian Advantage: With world class infrastructure to support early phase clinical research studies with speed, quality and cost advantages, Australia is also the ideal destination to conduct non-GLP and GLP toxicology studies to support FIH regulatory approval.
Quality
Our veteran team is dedicated to upholding the highest standards of quality, excellence, and integrity, while rigorously implementing the 3Rs in line with international regulatory guidelines
Speed
Attentive, coupled with Australia, provides the world’s fastest and most efficient regulatory process to get to First-in-Human trials. Following the completion of nonclinical studies, clinical trial approval is achieved within 4-5 weeks.
Cost
Established since July 2011, The Australian Government’s generous R&D Tax Incentive allows eligible biotechs to access up to 43.5% cash refund on R&D activities undertaken in Australia. Includes non-clinical activities undertaken in the US where there aren’t any solutions in Australia.
Holly Stefl, CEO, Attentive Science Australia
Holly, CEO and Co-Founder of Attentive Science Australia Pty Ltd, brings over two decades of pharmaceutical and research expertise to her leadership role. Her extensive experience encompasses both nonclinical and clinical trials, as well as in-vitro drug metabolism, DDI studies, regulated bioanalysis and toxicology services across a range of species, reflecting her deep understanding of drug development on a global scale.
Holly's career journey has been characterized by various leadership positions, including roles at Quintiles phase I clinical research unit in Overland Park, Kansas, and as Director of Clinical Operations in a small oncology biotech. Her relocation to Sydney, Australia with IQVIA further broadened her expertise, enabling her to guide emerging biotechs across the US, EU, and APAC regions in navigating the complex landscape of conducting clinical trials in Australia.
Driven by her passion for improving patient outcomes, Holly is committed to bringing new life-transforming treatments to fruition. She prioritizes excellence in bioanalytical and toxicology services for new medicines, particularly where there aren’t any solutions and achieving successful clinical outcomes